Earkart (544549)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 45.13% suggests strong capital efficiency, though debt and equity details are missing.
• Latest quarter remains profitable with ₹22 Cr sales and ₹2 Cr net profit.
• Niche medical equipment and supplies segment can offer high-margin opportunities if scaled.
• Small market cap of ₹205 Cr leaves room for meaningful growth if operations stabilise.

Concerns

• Sales declined 5.35% and net profit fell 44.11%, indicating deteriorating fundamentals.
• Piotroski F-Score of 3/9 points to weak overall financial health.
• P/E of 37.81 is expensive for a contracting business, leaving no margin of safety.
• Zero dividend, no promoter holding data, and no book value/debt disclosure reduce transparency.

AI Analysis

Let's begin with what I don't know. There is no book value, ROE, debt-equity ratio, or promoter holding disclosed. Graham would refuse to pay for a business he can't see. What I do see is a small medical equipment supplier at ₹149 with a market cap of ₹205 Cr. The trailing P/E of 37.81 is rich for a company whose sales fell 5.35% and profits collapsed 44.11%. A Piotroski score of 3 out of 9 reinforces that financial health is weak. The latest quarter, with sales of ₹22 Cr and net profit of ₹2 Cr, still shows a positive margin, but one quarter does not make a turnaround. ROCE of 45.13% is eye-catching, but with no debt or equity details, it may be a distorted metric from a thin capital base. I prefer predictable growth, moats, and decent returns on tangible capital. This has none of that visible. The zero dividend means I am not being paid to wait. At 37.8 times earnings, the market is already pricing in a strong recovery while the underlying business contracts. Buffett would say: 'Be fearful when others are greedy, and greedy when others are fearful.' Here, I am neither greedy nor fearful—I am confused, and confusion is not an investment thesis. For it to become attractive, Earkart must prove it can stabilize sales, rebuild profitability, and offer complete financials. Until then, this is a skip in my circle of competence.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer